About

Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.

About Us

Immunic Therapeutics

Immunic is developing a clinical pipeline of orally administered, small molecule therapies:

The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1, or Nurr1, activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase, or DHODH.

The company’s development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases.

Immunic, Inc. is headquartered in New York City…
Immunic, Inc. is headquartered in New York City. Its subsidiary, Immunic AG, is based in Gräfelfing near Munich, Germany, where the company’s research and development activities are conducted.
Immunic AG was founded in 2016 with...
Immunic AG was founded in 2016 with headquarters in Planegg-Martinsried, Germany. Since April 2019, the company has been operating under the name Immunic, Inc. with its registered office in the United States and has been trading on the Nasdaq Stock Market under the ticker symbol ”IMUX.”